Among other EGFR-TKIs, lazertinib, a new third-generation EGFR-TKI, is currently under investigation in combination with amivantamab, a bispecific antibody targeting MET and EGFR, in a phase I/Ib CHRYSALIS-2 study in patients with EGFR mutant NSCLC in progression on osimertinib. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.